TIVENIX

Changing the way neurological disorders are diagnosed

We decode the epigenetic signature of Alzheimer’s disease in plasma with the power of machine learning. We aim at providing accurate and non-invasive diagnosis of neurodegenerative diseases, as well as monitor their progression and response to treatment.

TIVENIX

AI-powered diagnostic platform

Tivenix’s proprietary software diagnostic can analyse and interpret complex epigenetic patterns in plasma with accuracy matching current best clinical practice for AD diagnostics. Our platform is engineered to easily integrate with data from other biomarkers.

TIVENIX

Our science is based on a solid biological rationale and supported by clinical evidence

We can detect and characterize neuronal loss in blood samples. Our proof-of-concept study demonstrated the accuracy of our biomarker for Alzheimer’s disease. We are now conducting a confirmatory study to validate our results and expand our scope to other neurodegenerative diseases.

TIVENIX

Our people

We are a Swiss company with a team of experts in neuroscience, biotechnology, data science, and software engineering. We are committed to innovation, excellence, and social impact. We believe that our technology can make a difference in the fight against Alzheimer’s disease and improve the lives of millions of people around the world.

Board of Directors

Luca Soncini

Chairman

Luca is a seasoned executive and advisor in the financial sector, with expertise in corporate governance, M&A, and banking strategies. He is also a lecturer and an active supporter of neuroscience research.

Paolo Paganetti

Board member

Paolo is an expert neuroscientist and cell biologist with a professional career of over thirty years in large pharma drug discovery, research and diagnostics industries, focussed primarly on neurodegenerative disorders. He is a former director and professor at leading research institutions in Switzerland.

Luca Bolzani

Board member

Luca is a seasoned leader and investor in the pharma industry, with a background in organic chemistry and a history of growing and exiting successful companies. He is also the chairman of Fondazione Agire, a foundation that supports innovation and entrepreneurship.

Miro Venturi

Board member

Miro brings over two decades of leadership in pharmaceutical R&D, biomarker development, and personalized medicine, with contributions to major global programs at Pfizer, Novartis, Roche, and academic institutions.

Management team

Giancarlo Faglia

CEO

With engineering and finance background, Giancarlo has been a manager and investor across diverse sectors. He has held senior positions in pharma companies, and currently serves as a board member of Sintetica and a senior manager of Swix Family Office.

Luca Colnaghi

Science & Innovation

Luca is a biotech entrepreneur and molecular biologist with a Ph.D. from NYU and a background in functional genomics and bioinformatics. He is an assistant professor at San Raffaele University, where he investigates the role of ubiquitin proteins in AD and he has also co-founded several biotech startup.

Rajbir Nath Batra

Technology

Experienced and dedicated senior scientist with a demonstrated history of working in cancer research (University of Cambridge/ German Cancer Research Center) and in Machine learning-based epidemiology (University of Oxford).

Paolo Paganetti

Clinical & Laboratory

Maurizio Callari

Bioinformatic

Maurizio is a computational biologist with extensive experience in bioinformatics and functional genomics. He holds a PhD in Functional Genomics from the University of Turin. He has authored over 170 publications and serves in editorial roles for journals like Frontiers in Oncology and Frontiers in Immunology.

Jessica Gilgenbach

Quality & Regulatory

Jessica is a strategic quality and regulatory expert with a strong track record in building high‑performing R&D and compliance organizations. She also serves as CEO of Smart Path and holds several additional C‑level roles across med‑tech companies.

Mario Sala

Finance & Accounting

Mario is a prominent financial with extensive experience in banking, Swiss and international taxation, financial analysis, accounting, and project management.

Thorsten Franke

Investor Relations

Scientific & Strategic Board

Ansgar Felbecker

Clinical Strategy, Medical KOL

Ansgar is a Swiss neurologist specializing in cognitive disorders and neurodegenerative diseases, with 15+ years of experience in clinical neurology, memory clinics, and biomarker-driven diagnostics. He serves as CEO of Neuro im Zentrum St. Gallen.

John Varaklis

Strategy, Regulatory

John is a digital health strategist with 30+ years of global clinical development experience at Novartis, Abbott, and Roche, where he led initiatives in wearable biosensing, remote data collection, and digital clinical innovation. He holds a B.Sc. in Biochemistry from Concordia University.

TIVENIX

Open to strategic investors who contribute more than capital—expertise, network, and strategic alignment.

Tivenix welcomes investors who believe in creating value through partnership—bringing experience, industry knowledge, and strategic collaboration beyond funding.

TIVENIX

News

07 | 2025

CellCarta and Tivenix Announce Strategic Partnership to Advance Blood-Based Diagnostics for Alzheimer’s Disease and other Neurodegenerative disorders.

Montreal, Canada & Lugano, Switzerland — July 21, 2025 – CellCarta, a global leader in precision medicine laboratory services, today announced a strategic partnership with Tivenix, a precision diagnostics company focused on neurodegenerative diseases. The

11 | 2023

Miro Venturi joins Tivenix’s Board of Directors

We are thrilled to announce that Miro Venturi has joined Tivenix SA as a board member! Miro brings a wealth of experience and expertise to our team, and we’re incredibly excited to have him on board. His strategic vision and

TIVENIX

Contact Us

We are looking for business partners that share our vision and want to collaborate in developing our platform.

If you are interested in learning more about our platform, our company, or our vision, please contact us.

We would love to hear from you and collaborate with you.